Related Experiment Video

Updated: Oct 11, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.8K

Novel emerging biomarkers to immunotherapy in kidney cancer

Yasser Ged1, Martin H Voss2

  • 1Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.

Therapeutic Advances in Medical Oncology
|December 6, 2021
PubMed

Insights

Novel biomarkers are emerging for metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI). Understanding these predictive markers could improve treatment selection and patient outcomes in mRCC.

Area of Science:

  • Oncology
  • Immunotherapy
  • Genomics

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has advanced with immune checkpoint inhibitors (ICIs).
  • Patient responses to ICIs vary, necessitating effective salvage therapies for non-responders.
  • Molecular omics technologies have accelerated biomarker discovery for mRCC.

Purpose of the Study:

  • To review emerging predictive biomarkers for immune checkpoint inhibitor (ICI) therapy in metastatic renal cell carcinoma (mRCC).
  • To bridge the gap between molecular insights and clinical application of biomarkers in mRCC treatment.

Main Methods:

  • Review of recent scientific literature on molecular omics and biomarker discovery in mRCC.
  • Analysis of emerging predictive biomarkers associated with ICI response in mRCC.

Main Results:

  • Significant progress has been made in identifying molecular underpinnings of the tumor microenvironment in mRCC.
  • Despite advancements, predictive biomarkers for ICI therapy have not been widely integrated into clinical practice for mRCC.

Conclusions:

  • Emerging predictive biomarkers show promise for personalizing ICI treatment in mRCC.
  • Further research and clinical validation are needed to integrate these biomarkers into standard mRCC care.
Keywords:
RCCbiomarkersimmune checkpointprecision medicine

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
725
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
82